This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations
1 Citations
Facts about Retinal dehydrogenase 2.
. .
Human | |
---|---|
Gene Name: | ALDH1A2 |
Uniprot: | O94788 |
Entrez: | 8854 |
Belongs to: |
---|
aldehyde dehydrogenase family |
aldehyde dehydrogenase 1 family, member A2; Aldehyde dehydrogenase family 1 member A2; ALDH 1A2; ALDH1A2; EC 1.2.1; EC 1.2.1.36; RALDH 2; RALDH; RALDH(II); RALDH2; RALDH2MGC26444; RALDH2-T; retinal dehydrogenase 2; Retinaldehyde-specific dehydrogenase type 2
Mass (kDA):
56.724 kDA
Human | |
---|---|
Location: | 15q21.3 |
Sequence: | 15; NC_000015.10 (57953424..58065923, complement) |
Cytoplasm.
This Boster bio review will focus on the benefits of ALDh2A2 Marker, and how it can be used in research. This tutorial will teach you how to capture the marker using an anti DDK affinity column. This method is universally applicable and can be used by all scientists. Here are some of these best uses for the ALDh2A2Marker. You can find more information on this topic in the following links.
A recent study showed that NUSAP1 protein expression was associated in predicting prognosis within a TCGA/CESC group. This study examined the relationship between NUSAP1 expression and the progression of CESCs, and found that NUSAP1 was associated with the clinical stage, overall survival, and disease-free survival. This study also identified additional associations between NUSAP1 expression and prognosis.
This study identified an ALDh2A2 genetic variant in the TCGA/CESC group. This mutation was also detected in a small group of subjects who have a high rate of cancer. ALDh2A2 expression appears to be an advantageous pre-requisite for tumor growth. It may also serve as a "prerequisite", to activate other oncogenic pathways.
Previous studies using the TCGA/CESC cohort have shown several prognostic factors for patients with CESC. A risk score calculated from 15 lncRNAs predicted CESC patient survival. Shi et al. Shi et.al. uncovered seven prognostic microRNAs that had an AUC of 0.8997. The study results suggest that CESC's ALDh2A2 gene may be a potential prognostic indicator.
The TCGA/CESC cohort suggests that the ALDh2A2 expression pattern may be a useful marker for understanding CESC molecular mechanisms. The presence of ALDh2A2 variants in the genome may also be a marker for poor survival in CESC. Further research is needed in order to confirm the association between ALDh2A2 (CESC) and this gene variant.
Although the study only included a single gene, the ALDh2A2 protein was detected in 40% of the cohort. The high expression of ALDh2A2 mRNA was most common in T-ALL (the most common type of cancer). This study also included samples derived from cervical carcinoma, as well as other types. These findings are promising, and may improve patient management as well as prognosis.
In addition to supporting cellular metabolism, ALDh2A2 supports energy production in T-cell ALCL cells. The CellTiter Glo test was used to analyze this data. This study analyzed the ALDh2A2 markers in patients and also evaluated the ALDH activity levels in T-cell ALCL. The ALDh2A2 gene expression level was significantly associated with the survival of myoblast cells. The results revealed that a higher proportion of ALDHbr genes in the TCGA/CESC cohort is associated a increased risk of apoptosis.
Researchers have a growing number of candidate genes for the HPV-related gene promoter methylations signature as biomarker for cervical cancer. Although the clinical relevance of methylation biomarkers to cervical cancer is still unclear, it has been shown that cervical precancer is associated with increased methylation at CpG locations in the HPV16 gene. These sites are associated with a higher risk of cervical cancer and precancer, according to molecular analyses.
While there are many other factors that can impact HPV viral load this biomarker can be used to identify women at higher risk for persistent cervical infection. Because it is the number and size of infected cell, HPV viral loads can be used to indicate the viral burden. A high viral load is associated to a large number of virions, while a low viral load may indicate an incipient lesions. The initial study data are limited to HPV16.
The HPV-related genetic promoter methylations test uses pre-aliquoted amplification mixture tubes to amplify the HPV L1 genes and a human CFTR. The three-step procedure includes biotin labeled primers and a control. The median fluorescent intensities (MFI) for each type are reported. Positive results are those which exceed a predetermined threshold level.
APTIMA can determine whether the targeted HPVs are present or absent by generating a qualitative result. However, this test doesn't distinguish between high-risk HPV infections and low risk ones. It does have a similar sensitivity in detecting cervical cancer as other HPV related gene promoter signatures. These results are critical to establishing an accurate HPV diagnosis.
The high levels of methylation found in the cervical epithelium suggest a potential role in developing a vaccine to prevent cervical cancer. This vaccine could reduce the need for cervical cancer screenings, which is the main cost associated with HPV-related cancer in developed countries. With the introduction of a cervical cancer vaccine, this risk should disappear. If this is true, the vaccine must be considered as an option.
The ALDh2A2 protein is an immunomodulatory molecule with anti-tumor activity. This anticancer agent can stimulate PD-1 production, promote PD-L1+ macrophage expansion, as well increase the number CD39 (+) regulatory T cell cells. It also increases the frequency of M2 macrophages and CD39(+) regulatory T cells.
The ALDh2A2 Marker was developed to determine if treatment with ALDh2A2 inhibited the growth of ovarian cancer cells. The cells were then seeded in 96 well plates on the days 3 to 15. After 24 hours, the cells were rinsed with 10% Cell Counting kit-8 (CCK8) in 100mL RPMI 1640 medium. Cell proliferation was determined by measuring the absorbance at 450 nm, and the ALDh2A2 molecule was found to decrease proliferation of cells.
The ALDh2A2 Marker can be used to assess cancer cells in many ways. The ALDH activity is currently a universal CSC marker but may be specific for some types. ALDH activity can vary depending on the tissue type. Therefore, it is important to identify which isoforms will be most suitable for certain types of cancers. For example, a human monocytic cell model correlates ALDH activity with M2 polarization.
The ALDh2A2 Marker can be used to identify patients who are at highest risk of developing lung cancer. It may be an early biomarker of GBM progression or recurrence. It is also a potential drug target for stem-cell-directed therapy. This marker has the potential of being an important tool in the detection of cancer stem cells. However, it is not a perfect biomarker.
It is not yet clear how the ALDh2A2Marker will be of any use in the future. ALDH is a gene that is involved in cell differentiation. However, it could also play a role during tissue regeneration. Further, the study of the ALDh2A2 Marker may open new vistas in many areas of science. It could be used for tissue regeneration and oncology.
The ALDh2A2 Marker is beneficial for epithelial ovarian cancer. In this study, researchers found that overexpression of ALDh2A2 suppressed the growth and migration of two epithelial ovarian cancer cell lines. The good prognosis of this cancer is also associated with high levels ALDh2A2. The ALDh2A2 Marker has many other benefits.
PMID: 9819382 by Ono Y., et al. TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3.
PMID: 29240402 by Chen Y., et al. Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors.
*More publications can be found for each product on its corresponding product page